Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide
about
Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivoRecent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancersDual functionality nanobioconjugates targeting intracellular bacteria in cancer cells with enhanced antimicrobial activity.Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanismsA novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer.Dexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: a novel application in pediatric nanomedicine.Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatmentGefitinib loaded folate decorated bovine serum albumin conjugated carboxymethyl-beta-cyclodextrin nanoparticles enhance drug delivery and attenuate autophagy in folate receptor-positive cancer cellsFertility preservation in women with cancer.Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acidsVascular disrupting agent arsenic trioxide enhances thermoradiotherapy of solid tumors.3D tumor tissue analogs and their orthotopic implants for understanding tumor-targeting of microenvironment-responsive nanosized chemotherapy and radiation.Targeted Proteomics Enables Simultaneous Quantification of Folate Receptor Isoforms and Potential Isoform-based Diagnosis in Breast Cancer.Inherently stealthy and highly tumor-selective gold nanoraspberries for photothermal cancer therapy.Acid-labile mPEG-vinyl ether-1,2-dioleylglycerol lipids with tunable pH sensitivity: synthesis and structural effects on hydrolysis rates, DOPE liposome release performance, and pharmacokinetics.Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances.Therapeutic Potential of Delivering Arsenic Trioxide into HPV-Infected Cervical Cancer Cells Using Liposomal NanotechnologyTriggered release of pharmacophores from [Ni(HAsO₃)]-loaded polymer-caged nanobin enhances pro-apoptotic activity: a combined experimental and theoretical study.pH-responsive biodegradable assemblies containing tunable phenyl-substituted vinyl ethers for use as efficient gene delivery vehicles.The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesisUrokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy.Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes.Metal-organic frameworks as potential drug carriers.Targeting liposomes toward novel pediatric anticancer therapeutics.The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment.Recent advances in understanding the role of diet and obesity in the development of colorectal cancer.Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic.Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects?Potential Use of Polyamidoamine Dendrimer Conjugates with Cyclodextrins as Novel Carriers for siRNA.Therapeutic and analytical applications of arsenic binding to proteins.Downregulation of hemojuvelin prevents inhibitory effects of bone morphogenetic proteins on iron metabolism in hepatocellular carcinoma.Involvement of autophagy in antitumor activity of folate-appended methyl-β-cyclodextrin.Recent advances in cyclodextrin delivery techniques.Recent progress in drug delivery of pluronic P123: pharmaceutical perspectives.A facile route to core-shell nanoparticulate formation of arsenic trioxide for effective solid tumor treatment.Overcoming concealment effects of targeting moieties in the PEG corona: controlled permeable polymersomes decorated with folate-antennae for selective targeting of tumor cells.Beyond platinum: synthesis, characterization, and in vitro toxicity of Cu(II)-releasing polymer nanoparticles for potential use as a drug delivery vector.Potential use of the complex of doxorubicin with folate-conjugated methyl-β-cyclodextrin for tumor-selective cancer chemotherapy.Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.Targeting of herbal bioactives through folate receptors: a novel concept to enhance intracellular drug delivery in cancer therapy.
P2860
Q28488457-D1A75666-812B-4DA6-8252-C2771088E2A1Q33768666-E0637A3B-19EC-4488-A3E9-236AEA744804Q33918385-D31BFE9C-02AD-4FEC-980F-C52824F4C0AEQ34020461-995E3A10-625F-4641-82AE-63D711A5923AQ34145056-7220019E-11F8-49C3-9BBF-67AD51E2D57EQ34171019-E2AFBCB0-7330-40B9-BEB1-67656F82E94AQ34298657-0C383E81-EDB1-4C2D-8F33-09DAFBB1DAC3Q34447234-5F57DCEE-E4B7-43A3-BC62-FFEE5D33A9C0Q34729392-D97D2507-EFB3-43C9-ADC1-3B7F7CA5FC19Q35613117-9A548A32-EA60-4D4E-9992-C80C5D8CCBC6Q35681405-BBAD7AAC-72AC-4CF0-AB9F-D15AFEE1F1F4Q35994548-4CA86087-8097-4E74-A96F-E9E9661F95FDQ36287593-05A970EE-3D23-4BA7-930F-CBA52E5D4319Q36293954-9CE7B81C-5760-460B-B38A-464CFA8D25DCQ36374025-DE7A1245-824B-431F-860D-A1C3EC9B46D9Q36589179-404F3A8D-5952-48DD-A009-C3C0806355B8Q36594617-41F8701D-D883-47A0-A398-58153C02A53DQ36831950-EE3AB28D-9E5B-458F-AFA4-00C9826BAC13Q37087260-6A66E155-4A6E-497C-AB0D-C7C6CF1788A8Q37220014-1363320B-4D5C-4EEE-B449-5F6D4956ACFDQ37451733-343E1BD0-82E8-4FEA-947B-5F7E9F1E977DQ37486703-DC926518-DB9F-4933-849A-320DE3EA02DAQ37673478-13FAAFD9-CBE0-4DD3-8562-C0A8D1286197Q37684734-3E57404F-FF6A-4C34-A77E-8798E47FFE74Q37717652-767D6359-7699-4DD5-922A-EAB90092B9F1Q37850852-E9CA9776-A64D-48F1-A177-72D63D0FD7A3Q37895294-E7184CA7-D660-4E2A-BD43-2233E593B515Q38166454-0921C30C-C26F-4C83-8A1C-C6967091D303Q38167284-0A016F92-CDD6-444C-9000-8F3B69CC2293Q38263881-85AFE601-D472-4525-A91B-734ACF37C8A1Q38332451-91C613B9-D721-4682-A4B9-BF9F27E2EC4DQ38367036-274BB515-5964-49D7-97A3-11D3EF8BD2F0Q38534300-EC1C9EB9-6E93-4B90-ACEB-1C8F3030770CQ38764283-E1F11B3F-C03F-4E66-A397-3FAF490B909CQ38796959-88551650-35DE-4665-AB62-4D5238185B5CQ38943361-3248DD62-2673-4D66-9980-7E68844A96D0Q39002265-FBFFFAFF-3FEE-42ED-8A48-BC9DE68FDE93Q39064107-964DF081-4ADB-48AA-AD79-E05B54F0C7D6Q39079389-3F011796-B3F8-4B6C-A2D0-6FC060054C8CQ39092356-B969184A-ADCA-4BE3-B4F1-80272302A538
P2860
Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Folate-mediated intracellular ...... ormulation of arsenic trioxide
@ast
Folate-mediated intracellular ...... ormulation of arsenic trioxide
@en
Folate-mediated intracellular ...... ormulation of arsenic trioxide
@nl
type
label
Folate-mediated intracellular ...... ormulation of arsenic trioxide
@ast
Folate-mediated intracellular ...... ormulation of arsenic trioxide
@en
Folate-mediated intracellular ...... ormulation of arsenic trioxide
@nl
prefLabel
Folate-mediated intracellular ...... ormulation of arsenic trioxide
@ast
Folate-mediated intracellular ...... ormulation of arsenic trioxide
@en
Folate-mediated intracellular ...... ormulation of arsenic trioxide
@nl
P2093
P2860
P1476
Folate-mediated intracellular ...... ormulation of arsenic trioxide
@en
P2093
David H Thompson
Haimei Chen
Jeroen Van den Bossche
Thomas V O'Halloran
P2860
P304
P356
10.1158/1535-7163.MCT-09-0045
P577
2009-06-30T00:00:00Z